The rise of Sildenafil initially sparked a surge for major pharmaceutical companies, however recent developments present a uncertain scenario for shareholders. Generic versions are eating into revenue, and persistent https://phoebelkxb398579.sharebyblog.com/41061667/the-blue-pill-and-big-pharma-a-risky-bet